Literature DB >> 24337206

[General substance classification and pharmacology of glaucoma].

H Thieme1, G Renieri, C Schuart.   

Abstract

The pharmaceutical therapy of glaucoma dates back to 1875 when Weber introduced pilocarpine into the medicinal treatment of glaucoma. Since then there has been a continuous development of topical antiglaucoma therapy whereby the main developments date back to the 1980s and 1990s. All forms of medicinal therapy aim at lowering the intraocular pressure and achieve this either by inhibiting aqueous humor secretion into the ciliary body or by enhancing physiological drainage routes along Schlemm's canal. This article gives an overview over the most important classes of antiglaucoma drugs, the indications and contraindications as well as pharmacological characteristics. The focus lies on the market of combination and generic drug preparations that is currently rapidly developing and therefore needs to be discussed in detail.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337206     DOI: 10.1007/s00347-012-2676-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  13 in total

1.  Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report.

Authors:  B BECKER
Journal:  Am J Ophthalmol       Date:  1954-01       Impact factor: 5.258

Review 2.  The uveoscleral outflow routes.

Authors:  S F Nilsson
Journal:  Eye (Lond)       Date:  1997       Impact factor: 3.775

3.  Fixed-dose combinations improve medication compliance: a meta-analysis.

Authors:  Sripal Bangalore; Gayathri Kamalakkannan; Sanobar Parkar; Franz H Messerli
Journal:  Am J Med       Date:  2007-08       Impact factor: 4.965

4.  Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits.

Authors:  C B Camras; L Z Bito; K E Eakins
Journal:  Invest Ophthalmol Vis Sci       Date:  1977-12       Impact factor: 4.799

5.  Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility.

Authors:  Hagen Thieme; Christin Schimmat; Galina Münzer; Marianne Boxberger; Michael Fromm; Norbert Pfeiffer; Rita Rosenthal
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

6.  Apraclonidine. A one-week dose-response study.

Authors:  H D Jampel; A L Robin; H A Quigley; I P Pollack
Journal:  Arch Ophthalmol       Date:  1988-08

7.  Effects of pilocarpine on the morphology of the human outflow apparatus.

Authors:  I Grierson; W R Lee; S Abraham
Journal:  Br J Ophthalmol       Date:  1978-05       Impact factor: 4.638

8.  Effects of apraclonidine on aqueous humor dynamics in human eyes.

Authors:  C B Toris; M E Tafoya; C B Camras; M E Yablonski
Journal:  Ophthalmology       Date:  1995-03       Impact factor: 12.079

9.  Can the concentration of timolol or the frequency of its administration be reduced?

Authors:  S L Letchinger; D Frohlichstein; D K Glieser; E J Higginbotham; J T Wilensky; M A Viana; R Zeimer
Journal:  Ophthalmology       Date:  1993-08       Impact factor: 12.079

10.  Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985.

Authors:  W L Nelson; F T Fraunfelder; J M Sills; J B Arrowsmith; J N Kuritsky
Journal:  Am J Ophthalmol       Date:  1986-11-15       Impact factor: 5.258

View more
  1 in total

1.  Concise Synthesis of Both Enantiomers of Pilocarpine.

Authors:  Theresa Schmidt; Niels Heise; Kurt Merzweiler; Hans-Peter Deigner; Ahmed Al-Harrasi; René Csuk
Journal:  Molecules       Date:  2021-06-16       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.